focus -WSS

focus

author：hotspot 2025-10-01 23:00:43 - browse：561

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Will the market for weight loss drugs really reach $100 billion?

entertainment

focus

WSS

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

In search for therapies for solid tumors, companies turn to claudin

As biotech industry slumps, bioscience job market is upside down

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

UnitedHealth’s Optum accused of antitrust violations in California

Organ aging and disease risk measured by new blood test

explore

focus

hotspot

Affirmative action in medical school literally saved lives

Flagship Pioneering launches a new biotech in two countries

Tori Bowie and the unacceptable rates of Black maternal death

Why getting cancer drugs just got harder for rural patients

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Mayo Clinic plans $5B tech

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

explore

Takeda, Janssen join wearable maker to measure scratching

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

FogPharma raises $145 million in rare Series E round

Change Healthcare cyberattack outage could last weeks

Rep. Raul Ruiz on the physician shortage and more

With clinical trial data readouts, here's how to spot spin

leisure time

entertainment

focus

hotspot